{"filing":{"accession_number":"0001213900-26-089912","cik":"0000822370","ticker":"EMMA","company_name":"Emmaus Life Sciences, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"ea0302099-8k_emmaus.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/ea0302099-8k_emmaus.htm"},"events":[{"id":27844,"run_id":25418,"accession_number":"0001213900-26-089912","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Emmaus Life Sciences issued a press release on August 14, 2026 announcing its results of operations and financial condition for the three and six months ended June 30, 2026. The disclosure includes detailed financial statements (condensed consolidated statement of operations and balance sheets), revenue analysis showing a 124% increase in net revenues due to the NIT license arrangement, operating expense reductions, and net income of $1.3 million for the quarter. This is a standard quarterly earnings release with material financial results that would affect a reasonable investor's assessment of the company's performance.","company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29544,"accession_number":"0001213900-26-089912","item_number":"2.02","item_title":"Results of Operation and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Emmaus Life Sciences issued a press release on August 14, 2026 announcing its results of operations and financial condition for the three and six months ended June 30, 2026. The disclosure includes detailed financial statements (condensed consolidated statement of operations and balance sheets), revenue analysis showing a 124% increase in net revenues due to the NIT license arrangement, operating expense reductions, and net income of $1.3 million for the quarter. This is a standard quarterly earnings release with material financial results that would affect a reasonable investor's assessment of the company's performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T19:12:43.564292+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29544,"accession_number":"0001213900-26-089912","item_number":"2.02","item_title":"Results of Operation and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Emmaus Life Sciences issued a press release on August 14, 2026 announcing its results of operations and financial condition for the three and six months ended June 30, 2026. The disclosure includes detailed financial statements (condensed consolidated statement of operations and balance sheets), revenue analysis showing a 124% increase in net revenues due to the NIT license arrangement, operating expense reductions, and net income of $1.3 million for the quarter. This is a standard quarterly earnings release with material financial results that would affect a reasonable investor's assessment of the company's performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T19:12:43.564292+00:00","company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","filing_date":"2026-08-14"}]}